Α,N,N-Trimethyltryptamine

α,N,N-Trimethyltryptamine (α,N,N-TMT, α-TMT, or ATMT), also known as α-methyl-N,N-dimethyltryptamine (α-methyl-DMT or α-Me-DMT), as well as Alpha-N, is a psychedelic drug of the tryptamine family.^[1][2] It is similar in structure to other psychoactive tryptamines such as N,N-dimethyltryptamine (DMT) and α-methyltryptamine (αMT).^[2]

α,N,N-Trimethyltryptamine

Clinical data
Other names	α,N,N-TMT; α-TMT; ATMT; α-Methyl-N,N-dimethyltryptamine; α-Methyl-DMT; α-Me-DMT; Alpha-N
Routes of administration	Oral
Drug class	Serotonergic psychedelic; Hallucinogen
Identifiers
IUPAC name (2-(1H-Indol-3-yl)-1-methyl-ethyl)dimethylamine
CAS Number	4761-32-4 Y
PubChem CID	134080494
ChemSpider	59718639
UNII	8AV9QTP9HK
CompTox Dashboard (EPA)	DTXSID401336121
Chemical and physical data
Formula	C13H18N2
Molar mass	202.301 g·mol−1
3D model (JSmol)	Interactive image
SMILES CN(C)C(C)Cc2c[nH]c1ccccc12
InChI InChI=1S/C13H18N2/c1-10(15(2)3)8-11-9-14-13-7-5-4-6-12(11)13/h4-7,9-10,14H,8H2,1-3H3 Key:XQFCCTPWINMCQJ-UHFFFAOYSA-N
(verify)

The drug has been tested in animals and compared with αMT.^[2] It was found to produce similar effects, such as hyperlocomotion and reversal of reserpine-induced behavioral depression, but with only around half the potency of αMT.^[2] α,N,N-TMT was briefly mentioned by Alexander Shulgin in his 1997 book TiHKAL (Tryptamines I Have Known and Loved), but he did not mention having tested it and did not describe its effects, dosage, or duration.^[1] In 2025, Hamilton Morris described having synthesized and assayed α,N,N-TMT.^[3] He reported that it was an active psychedelic taken orally but was much less potent than AMT.^[3]

α,N,N-TMT was encountered as a novel designer drug in Europe by 2015.^[4]

See also

• α,N-Dimethyltryptamine (α,N-DMT)
• α,N,N,O-Tetramethylserotonin (α,N,N,O-TeMS)
• Ciclindole
• MPMI
• Zalsupindole